10/07/2025
Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles.
In a Phase I-II study treating glioblastoma and grade 4 astrocytoma at Skåne University Hospital in Sweden, ClearPoint has demonstrated:
- Improved survival compared to matched open surgery controls
- Reproducible workflow with no device-related complications
- Median ablation time of just 6.5 minutes
Visit at Booth 545 and see the results presented in Poster 3560. Product usage represented may not be approved or cleared in all markets.
https://loom.ly/Fv4xNnk
ClearPoint Neuro Announces Promising Results from Brain Tumor Laser Therapy Study to be Presented at the CNS Annual Meeting in Los Angeles October 07, 2025 4:15pm EDT Download as PDF SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"),....